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obtain consistent results, as well as including patient QOL 
evaluation to complement the clinician assessment. 
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Purpose/Objective: Adjuvant RT after quadrantectomy or 
lumpectomy plays an essential role in breast conserving 
therapy for early stage carcinoma and 60 Gy delivered in 30 
fractions in 6 weeks is generally considered the standard 
dose. The present study aims to evaluate acute, sub-acute 
and short term late side effects in patients with early stage 
breast cancer treated with adjuvant radiotherapy (RT) using 
concomitant boost. 
Materials and Methods: Between June 2010 and October 
2013, 586 patients (median age 60 years, range 27-96 years) 
with early-stage breast cancer were treated with a 
hypofractionated schedule of external beam RT after 
conserving surgery; 143 patients underwent post-operative 
chemotherapy before starting RT. RT was delivered as follow: 
45 Gy in 20 fractions (225 cGy/fr) in 4 weeks to the whole 
breast and a daily concomitant boost dose (5Gy) to the 
lumpectomy cavity (25 cGy/fr). The cumulative nominal dose 
was 50 Gy. The technique used was 3D-conformational RT 
with 2 tangential fields for the whole breast and 2 oblique 
fields for the boost. The surgical bed was primarily defined 
with clips. Toxicity was scored according to LENT-SOMA 
scale. 
Results: Twenty-five patients experienced grade 3 skin 
toxicity within one week from the end of the RT course (eight 
after adjuvant chemotherapy administered before breast 
RT).  After 19-month median follow-up (range 12-52 months), 
no grade 4 toxicity were detected; only 5 patients 
experienced grade 3 skin toxicity and thirty-nine patients 
reported grade 2 breast pain. Concerning cosmetic results, 
one patients developed scar retraction; the others 585 
patients showed excellent or good cosmetic results. Disease 
recurrences were recorded in 4 patients: one of them with 
local relapse, the others three with systemic spread.  
Conclusions: The explored regimen seems to be feasible 
providing consistent clinical results with excellent toxicity 
profile.  
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Purpose/Objective: To evaluate a mathematical model, 
based on direct tumor indicators, for target volume 
delineation of breast cancer in prone position. 
Materials and Methods: Seven patients with unifocal, early 
stage breast cancer cT1-2 cN0 were prospectively enrolled. 
Patients were installed on our breast board, applying prone 
positioning with both arms elevated above the head and an 
inclination of 10-15° towards the ipsi-lateral breast. A 
preoperative CT-scan was performed on a Toshiba® 16-slice 
CT with 100cc Visipaque® injected intravenously and using 
our standard CT-protocol (5mm slices, 120kV). Four tattoos 
were applied to reproduce positioning at the moment of 
postoperative simulation, 4 to 6 weeks later. During 
tumorectomy an 'indicator' clip (9mm) was placed in the 
cavity wall at the level of the tumor to indicate depth of the 
tumor bed. Full thickness closure was performed. The 
postoperative simulation CT (non contrast-enhanced) was 
fused with the preoperative CT, based on visual correlation. 
Delineation protocol included: 
· GTVvisual: tumor delineation based on visual CT-fusion 
· GTVvector: tumor delineation based on deformation of tumor 
volume from preoperative to postoperative CT 
· CTVmath: a ‘mathematical’ sphere with axis defined as the 
center between the indicator clip and GTVvisual centers. A 
radius of 20mm was used (Holland, Vicini), minus the minimal 
excision margin (≤10mm). Thoracic wall was subtracted from 
the resulting sphere.  
· CTVstandard: volume at risk based on indirect indicators (clips, 
seroma, tissue distortion, scar, imaging…) according to 
standard delineation guidelines 
Results: We compared volumes and location of CTVmath with 
CTVstandard and their relation to tumor GTV. 
The small CTV volumes only partially explain low Jaccard 
Index for CTVmath vs. CTVstandard (0,35 SD 0,09). Distance of 
geometrical centers varies between 9,6 to 24,5mm (mean 
14,26mm, SD 4,7) indicating a substantial difference in target 
volume localization. Tumor GTV on pre-operative CT-scan is 
more frequently included in the CTV when a mathematical 
delineation is used (overlap 0,86, SD 0,21) versus standard 
delineation (0,68, SD 0,38). No substantial difference in CTV 
volumes is observed, partly due to larger caudo-cranial 
diameter of CTVmath. Clips were often placed onto the 
pectoral fascia, even with tumors located centrally in the 
breast.  
 
 
 
